Klin Onkol 2020; 33(Suppl 1): 80-85. DOI: 10.14735/amko2020S80.
Background: Conventionally fractionated radiotherapy for prostate cancer belongs to the longest radiotherapy courses. Shortening of the overall duration of the course not only brings a benefit to the patients, but also decreases the workload of radiation oncology departments. Material and methods: A total of 205 patients with prostate cancer were irradiated with the dose of 20 x 3.0 Gy to the prostate, 4 fractions a week (low risk) or 21 × 3.0/2.1 Gy to the prostate / 2/3 of seminal vesicles, 3 and 4 fractions a week alternately (intermediate and high risk). Results: Early toxicity by Radiation Therapy Oncology Group / European Organisation for Research and Therapy of Cancer (RTOG/EORTC): Genitourinary tract: G0 49%, G1 32%, G2 16%, G3 1% and G4 2%. Gastrointestinal tract: G0 79%, G1 19% and G2 2%. Late toxicity by Radiation Therapy Oncology Group / Fox Chase Cancer Center (RTOG/FC-LENT): The median follow-up is 5,1 years. Patients with the follow-up < 1 year were excluded. Genitourinary tract: G0 71%, G1 21%, G2 5%, G3 1% and G4 2%. Gastrointestinal tract: G0 83%, G1 13%, G2 11% and G3 1%. Conclusion: The fractionation scheme 20–21 × 3.0 Gy, 3–4-times a week seems to be a safe method according to the toxicity. For biochemical control evaluation, longer follow-up is needed.
